Myriad Genetics (MYGN) vs VolitionRX (VNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Myriad Genetics is the larger company by market cap ($414.2 million vs $6.6 million), about 63.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MYGN | VNRX |
|---|---|---|
| Share price | $4.33 | $0.2181 |
| Market cap | $414.16M | $6.56M |
| 1-day change | +3.10% | -0.59% |
| YTD return | -31.71% | — |
| 1-year return | -45.03% | — |
| 5-year return | -86.77% | — |
| EPS (TTM) | $-1.18 | $-3.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.59 | $10.40 |
| 52-week low | $2.74 | $0.2176 |
| Distance from 52-week high | -49.59% | -97.90% |
| Analyst consensus | hold | none |
| Avg. price target upside | -9.70% | +6144.84% |
| Average volume | 2.04M | 8.47M |
| Shares outstanding | 95.65M | 30.06M |
| Employees | 2,700 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Myriad Genetics is about 63.2 times larger than VolitionRX by market value ($414.16M vs $6.56M).
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
About VolitionRX
VNRX stock →VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 57 employees
MYGN vs VNRX FAQ
Which is bigger, Myriad Genetics or VolitionRX?
Myriad Genetics (MYGN) is larger, with a market capitalization of $414.16M compared with $6.56M for VolitionRX (VNRX).
Are Myriad Genetics and VolitionRX in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.